Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&D strategy
Pfizer CEO Ian Read got a little help from the FDA today in highlighting his recent pledge to rely on the late-stage pipeline for future revenue growth. The agency has stamped its approval on dacomitinib, a kinase inhibitor now headed for frontline duty against non-small cell lung cancer.
The drug has a narrowly defined role for cases involving an EGFR exon 19 deletion or exon 21 L858R substitution mutations. It will now be sold as Vizimpro.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.